EZH2 and cancer: This was the first report of an enhanced non-canonical interaction between the Ezh2Y641F mutant and a non-histone protein, suggesting that perhaps this is an important aspect of the oncogenic activity of EZH2 in cancers with Y641 mutations (7, 8).